October 19, 2023 News by Andrea Lobo, PhD ECTRIMS 2023: Most on Zeposia see slower disability progression More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the RADIANCE clinical trial and its extension study still haven’t experienced confirmed disability progression after eight years of follow-up, new…
October 18, 2023 News by Marisa Wexler, MS ECTRIMS 2023: New research may help explain EBV and MS link New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), and explain why only some people infected with EBV — previously found to raise the risk of MS by…
October 18, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Declining risk of SPMS conversion seen in registry The risk of converting to secondary-progressive multiple sclerosis (SPMS) has declined in recent years for patients who have an earlier disease onset, an analysis of data from the Swedish MS Registry indicates. The conversion is also occurring later…
October 18, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Sick days in years before diagnosis suggest MS prodrome Multiple sclerosis (MS) patients had significantly more sickness-related work absences in the years leading up to their disease onset than people in the general population, a recent Swedish analysis showed. Scientists believe the findings support the growing notion…
October 17, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Blood biomarker may help to predict disability in MS Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or two prior to disability worsening in people with multiple sclerosis (MS), particularly among patients whose disease progressed without…
October 17, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Early high-efficacy treatment helps to slow disability in pediatric-onset MS Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly if given in early disease stages when disabling symptoms are negligible. That’s according to data shared at the 9th…
October 17, 2023 News by Marisa Wexler, MS ECTRIMS 2023: Fenebrutinib lowers new lesions in relapsing MS Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in people with relapsing forms of multiple sclerosis (MS). Pharmacological data from the study suggest the anti-inflammatory experimental medication…
October 16, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Tolebrutinib found to show benefits for up to 3 years Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS), according to new data from the…
October 16, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Obesity tied to disability progression, declines Obese people with multiple sclerosis (MS) had faster disability accumulation, greater cognitive declines, and worse quality of life in the 15 years after diagnosis relative to patients with normal weight, according to an analysis of Swedish data. While…
